Drug Search Results
More Filters [+]

AZD-2327

Alternative Names: azd-2327, azd2327, azd 2327
Latest Update: 2012-11-08
Latest Update Note: Clinical Trial Update

Product Description

AZD2327 is a selective delta opioid receptor (DOR) agonist with anxiolytic and antidepressant activity in animal models. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/26728893/)

Mechanisms of Action: OPRD Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for AZD-2327

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Depressive Disorder, Major

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

AMDD

P2

Completed

Depressive Disorder, Major

2011-10-01

Recent News Events

Date

Type

Title